AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21457979 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 79
Study 19704401 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategies (LSS) for estimation of mycophenolic acid (MPA) AUC(0-12) after EC-MPS administration
Number of subjects: 109
Study 17646968 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glycine (0.8 g/kg)
Number of subjects: 14
Study 17646968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15142017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (L-CHO) diet
Number of subjects: 8
Study 15142017 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 8
Study 11583884 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio < 5 ULN
Number of subjects: 2918
Study 11583884 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio >= 5 to < 10 ULN
Number of subjects: 2918
Study 11583884 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio >= 10 to < 20 ULN
Number of subjects: 2918
Study 11583884 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio >= 20 ULN
Number of subjects: 2918
Study 9291244 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (INTEGRILIN)
Number of subjects: 0
Study 9291244 — intervention group
Group type: COMPARATOR
Intervention: Heparin and aspirin (current antithrombotic management)
Number of subjects: 0
Study 7706179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspoxicillin 4 g tds (n = 52)
Number of subjects: 105
Study 7706179 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 4 g qds (n = 53)
Number of subjects: 105
Study 3110654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (600 mg per diem b.i.d.)
Number of subjects: 30
Study 3110654 — intervention group
Group type: COMPARATOR
Intervention: Lysine acetylsalicylate (1800 mg per diem b.i.d.)
Number of subjects: 30
Study 29389819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training with an electronic audiovisual checklist app during at least 60 consecutive general anaesthesia inductions.
Number of subjects: 26
Study 29389819 — intervention group
Group type: COMPARATOR
Intervention: Normal training without the electronic checklist app.
Number of subjects: 26
Study 27175917 — intervention group
Group type: EXPERIMENTAL
Intervention: AORIF (Arthroscopically Assisted Open Reduction and Internal Fixation), n=37
Number of subjects: 74
Study 27175917 — intervention group
Group type: COMPARATOR
Intervention: ORIF (Open Reduction and Internal Fixation), n=37
Number of subjects: 74
Study 24472087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 200
Study 24472087 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser ablation
Number of subjects: 200
Study 24080607 — intervention group
Group type: EXPERIMENTAL
Intervention: New Harmonic Scalpel (NHS)
Number of subjects: 211
Study 24080607 — intervention group
Group type: COMPARATOR
Intervention: Conventional Hemostasis (CH)
Number of subjects: 211
Study 20886227 — intervention group
Group type: EXPERIMENTAL
Intervention: One-set resistance training (RT)
Number of subjects: 8
Study 20886227 — intervention group
Group type: COMPARATOR
Intervention: Three-set resistance training (RT)
Number of subjects: 8
Study 18299305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine, trivalent, administered intranasally, 2 doses, 35 +/- 7 days apart.
Number of subjects: 120
Study 18299305 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intranasally, 2 doses, 35 +/- 7 days apart.
Number of subjects: 120
Study 16974115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen-associated endometrial polyps
Number of subjects: 20
Study 16974115 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal polyps
Number of subjects: 20
Study 14622082 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered CBT (CBT12)
Number of subjects: 186
Study 14622082 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered CBT (CBT6)
Number of subjects: 186
Study 14622082 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-augmented CBT (CBT6-CA)
Number of subjects: 186
Study 14622082 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 186
Study 10998460 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat diet (21% energy from saturated fat, 3% energy from polyunsaturated fat)
Number of subjects: 55
Study 10998460 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet (11% energy as saturated fat, 10% energy as polyunsaturated fat)
Number of subjects: 55
Study 10998460 — intervention group
Group type: COMPARATOR
Intervention: Dietary compliance measures (changes in reported saturated and polyunsaturated fat intake)
Number of subjects: 55
Study 10998460 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride linoleate (reflecting polyunsaturated fat intake)
Number of subjects: 55
Study 8726156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide
Number of subjects: 23
Study 8726156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1431312 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interferon‐beta (rHuIFN‐beta)
Number of subjects: 12
Study 1431312 — intervention group
Group type: COMPARATOR
Intervention: natural IFN‐beta
Number of subjects: 12
Study 3888864 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 400 mg thrice daily for 30 days
Number of subjects: 150
Study 3888864 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg thrice daily for 30 days
Number of subjects: 150
Study 3888864 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 150
Study 3888864 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine laboratory tests
Number of subjects: 150
Study 31308274 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic tongue scraper
Number of subjects: 0
Study 31308274 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal tongue scraper
Number of subjects: 0
Study 31308274 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush with tongue scraper
Number of subjects: 0
Study 30570860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of crystalloids and a small colloid dose
Number of subjects: 80
Study 30570860 — intervention group
Group type: COMPARATOR
Intervention: Only crystalloid solutions
Number of subjects: 80
Study 26659366 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 2000 mg/m² day 1-14 (ARM A)
Number of subjects: 57
Study 26659366 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 2000 mg/m² day 1-14 + mitomycin C 6 mg/m² day 1 (ARM B)
Number of subjects: 57
Study 24661196 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Coenzyme Q10 per day
Number of subjects: 23
Study 24661196 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 23
Study 22809314 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation splint treatment
Number of subjects: 80
Study 22809314 — intervention group
Group type: COMPARATOR
Intervention: Counselling and masticatory muscle exercises (Control)
Number of subjects: 80
Study 20545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa with CM-URINE condition
Number of subjects: 136
Study 20545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa with CM-ATTEND condition
Number of subjects: 136
Study 20545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa with CM-MEDICATION condition
Number of subjects: 136
Study 20545388 — intervention group
Group type: COMPARATOR
Intervention: Placebo with CM-URINE condition
Number of subjects: 136
Study 20545388 — intervention group
Group type: COMPARATOR
Intervention: Placebo with CM-ATTEND condition
Number of subjects: 136
Study 20545388 — intervention group
Group type: COMPARATOR
Intervention: Placebo with CM-MEDICATION condition
Number of subjects: 136
Study 17921396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) 50,000 IU
Number of subjects: 2710
Study 17921396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2710
Study 16047057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 12 weeks)
Number of subjects: 32
Study 16047057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12394931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 12
Study 10420471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemithyl (bemactor)
Number of subjects: 0
Study 7484965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0155‐inch diameter multiple‐stranded stainless steel wire (Dentaflex)
Number of subjects: 74
Study 7484965 — intervention group
Group type: COMPARATOR
Intervention: 0.014‐inch diameter nickel‐titanium alloy wire (NiTi)
Number of subjects: 74
Study 2278337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 60
Study 2278337 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 60
Study 2278337 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 60
Study 2278337 — intervention group
Group type: COMPARATOR
Intervention: Control (reference values)
Number of subjects: 60
Study 373105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg/day)
Number of subjects: 50
Study 373105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 50
Study 373105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31483448 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 730
Study 31483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 730
Study 31483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Local recurrence
Number of subjects: 730
Study 31483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant recurrence
Number of subjects: 730
Study 31483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant-only recurrence
Number of subjects: 730
Study 31483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Local with distant recurrence
Number of subjects: 730
Study 31483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Only local recurrence
Number of subjects: 730
Study 28113040 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic procedure (group B)
Number of subjects: 52
Study 28113040 — intervention group
Group type: COMPARATOR
Intervention: Open procedure (group A)
Number of subjects: 52
Study 26456726 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to leprosy patients in the workplace
Number of subjects: 280
Study 23896332 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWT on a 10m course
Number of subjects: 45
Study 23896332 — intervention group
Group type: COMPARATOR
Intervention: 6MWT on a 30m course
Number of subjects: 45
Study 20930643 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b plus ribavirin therapy
Number of subjects: 4913
Study 20930643 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b plus ribavirin therapy continued post-seizure
Number of subjects: 4913
Study 19343014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP): 25% protein
Number of subjects: 95
Study 19343014 — intervention group
Group type: COMPARATOR
Intervention: Standard protein diet (SP): 15% protein
Number of subjects: 95
Study 19343014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (HP and SP)
Number of subjects: 95
Study 16704650 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 5 mg daily
Number of subjects: 22
Study 16704650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15100668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program including avoidance of house dust mite, pet allergen, and environmental tobacco smoke; encouragement of breast-feeding with formula supplementation; delayed introduction of solid foods
Number of subjects: 545
Study 15100668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 545
Study 15100668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program
Number of subjects: 545
Study 15100668 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 545
Study 11841194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindagel (clindamycin phosphate 1% gel), administered once daily
Number of subjects: 0
Study 11841194 — intervention group
Group type: COMPARATOR
Intervention: Cleocin T (slightly different gel formulation), indicated for twice-daily use
Number of subjects: 0
Study 9728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 250 mg once daily
Number of subjects: 1479
Study 9728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg once daily
Number of subjects: 1479
Study 9728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1 g once daily
Number of subjects: 1479
Study 9728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 250 mg twice daily
Number of subjects: 1479
Study 9728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 1479
Study 9728526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1479
Study 8031815 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus exercise
Number of subjects: 9
Study 8031815 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 9
Study 2738998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone spray
Number of subjects: 0
Study 2738998 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 0
Study 15571711 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, intensive treatment from 3 to 12 months post-stroke
Number of subjects: 18
Study 31834164 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-based portable navigation system
Number of subjects: 46
Study 31834164 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand technique (mechanical alignment guide)
Number of subjects: 46
Study 31079137 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized 3D printed insoles
Number of subjects: 80
Study 31079137 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated insoles
Number of subjects: 80
Study 28096758 — intervention group
Group type: EXPERIMENTAL
Intervention: PWS (pre-workout dietary supplement)
Number of subjects: 25
Study 28096758 — intervention group
Group type: EXPERIMENTAL
Intervention: PWS + S (pre-workout dietary supplement with p-synephrine)
Number of subjects: 25
Study 28096758 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 25
Study 26086833 — intervention group
Group type: EXPERIMENTAL
Intervention: Iminoral
Number of subjects: 221
Study 26086833 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 221
Study 24300486 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 0
Study 24300486 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil
Number of subjects: 0
Study 22107734 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid supplementation (1 gram per day) plus exercise training (30 minutes a day, 5 days per week for 12 weeks)
Number of subjects: 24
Study 22107734 — intervention group
Group type: COMPARATOR
Intervention: α-lipoic acid supplementation only (1 gram per day for 12 weeks)
Number of subjects: 24
Study 20441061 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg TDS) until the end of 8 weeks gestation (Group B)
Number of subjects: 75
Study 20441061 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg TDS) until the end of 12 weeks gestation (Group C)
Number of subjects: 75
Study 20441061 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg TDS) stopped immediately after diagnosis of pregnancy (Group A)
Number of subjects: 75
Study 17022766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis administered three times a day to all neonates (Group B)
Number of subjects: 3991
Study 17022766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis for yeast carriers (Group A1)
Number of subjects: 3991
Study 17022766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis for non-yeast carriers (Group A2)
Number of subjects: 3991
Study 17022766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis (Groups A1 and A2 combined)
Number of subjects: 3991
Study 17022766 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 3991
Study 15333855 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic continuous positive airways pressure (CPAP) for 1 month
Number of subjects: 220
Study 15333855 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic continuous positive airways pressure (CPAP) for 1 month
Number of subjects: 220
Study 10947033 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release caffeine 150 mg
Number of subjects: 24
Study 10947033 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release caffeine 300 mg
Number of subjects: 24
Study 10947033 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release caffeine 600 mg
Number of subjects: 24
Study 10947033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9709282 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 8
Study 8279669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare
Number of subjects: 0
Study 8279669 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 0
Study 2894787 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 micrograms.kg‐1 fazadinium
Number of subjects: 36
Study 2894787 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 micrograms.kg‐1 pancuronium
Number of subjects: 36
Study 2894787 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 micrograms.kg‐1 gallamine
Number of subjects: 36
Study 2894787 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 micrograms.kg‐1 d‐tubocurarine
Number of subjects: 36
Study 29251282 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor antagonist amisulpride
Number of subjects: 0
Study 29251282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28704263 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertising
Number of subjects: 0
Study 28704263 — intervention group
Group type: COMPARATOR
Intervention: Conventional recruitment methods
Number of subjects: 0
Study 26069111 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC group (n=29)
Number of subjects: 58
Study 26069111 — intervention group
Group type: COMPARATOR
Intervention: NICOM group (n=29)
Number of subjects: 58
Study 21904194 — intervention group
Group type: COMPARATOR
Intervention: Group A: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL sterile water intrathecally
Number of subjects: 75
Study 21904194 — intervention group
Group type: COMPARATOR
Intervention: Group B: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (200 μg) nalbuphine intrathecally
Number of subjects: 75
Study 21904194 — intervention group
Group type: COMPARATOR
Intervention: Group C: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (400 μg) nalbuphine intrathecally
Number of subjects: 75
Study 22001132 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training 1 (CT1)
Number of subjects: 10
Study 22001132 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training 2 (CT2)
Number of subjects: 10
Study 22001132 — intervention group
Group type: COMPARATOR
Intervention: Control Session (CS)
Number of subjects: 10
Study 22001132 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 10
Study 18982918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 18982918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (once-weekly regimen)
Number of subjects: 0
Study 16412443 — intervention group
Group type: EXPERIMENTAL
Intervention: MS specialist nurse programme
Number of subjects: 616
Study 16412443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MS nurse posts)
Number of subjects: 616
Study 12887480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily for 2 years
Number of subjects: 4325
Study 12887480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4325
Study 12887480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 4325
Study 10100557 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + MTX
Number of subjects: 30
Study 10100557 — intervention group
Group type: COMPARATOR
Intervention: CsA alone
Number of subjects: 30
Study 10100557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CsA + MTX and CsA alone)
Number of subjects: 30
Study 10100557 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 30
Study 10100557 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute leukemia
Number of subjects: 30
Study 8901155 — intervention group
Group type: EXPERIMENTAL
Intervention: Test patch (Dermestril)
Number of subjects: 28
Study 8901155 — intervention group
Group type: COMPARATOR
Intervention: Reference patch
Number of subjects: 28
Study 1746424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/day
Number of subjects: 4000
Study 1746424 — intervention group
Group type: COMPARATOR
Intervention: Inactive drug therapy (control)
Number of subjects: 4000
Study 7048879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (mean dose 28 +/- 5 mg twice a day)
Number of subjects: 30
Study 7048879 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (673 +/- 158 mg three times a day)
Number of subjects: 30
Study 30653147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-administration of remifentanil before propofol infusion (Group R)
Number of subjects: 60
Study 30653147 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of remifentanil with propofol (Group N)
Number of subjects: 60